Use of Real-World Evidence to Support FDA Approval of Oncology Drugs

Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the efficacy of oncology drugs for Food and Drug Administration (FDA) approval has not been described. In this paper, we review 5 recent examples where...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health 2020-10, Vol.23 (10), p.1358-1365
Hauptverfasser: Feinberg, Bruce A., Gajra, Ajeet, Zettler, Marjorie E., Phillips, Todd D., Phillips, Eli G., Kish, Jonathan K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1365
container_issue 10
container_start_page 1358
container_title Value in health
container_volume 23
creator Feinberg, Bruce A.
Gajra, Ajeet
Zettler, Marjorie E.
Phillips, Todd D.
Phillips, Eli G.
Kish, Jonathan K.
description Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the efficacy of oncology drugs for Food and Drug Administration (FDA) approval has not been described. In this paper, we review 5 recent examples where RWE was submitted in support of the FDA approvals of original or supplementary indications for oncology drugs. To identify cases where RWE was used, we reviewed drug approval packages available at Drugs@FDA for oncology drugs approved between 2017 and 2019. Five cases were selected to present a broad overview of different types of RWE, different circumstances under which RWE has been used for regulatory approvals, and how FDA evaluated the data in each case. The type of RWE submitted, the indication, limitations identified by FDA reviewers, and the outcome of the submission are discussed. RWE, particularly historical controls for rare or orphan indications, has been used to support both original and supplementary oncology drug approvals. Types of RWE included data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies. Small sample sizes, data quality, and methodological issues were among concerns cited by FDA reviewers. By bridging the gap between the constraints of the trial setting and the realities of clinical practice, RWE can add value to a regulatory submission. These early examples provide insight into how regulators evaluated RWE submitted as evidence of efficacy for oncology drugs. •In accordance with the 21st Century Cures Act directive, the Food and Drug Administration (FDA) is evaluating the potential for real-world evidence (RWE) to support the approval of supplementary indications or fulfill post-approval study requirements for drugs.•Our analysis found that significant precedent exists for the FDA’s acceptance of RWE (including data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies) to support oncology drug approvals, especially for rare or orphan indications.•The use of RWE to support drug approval is a viable strategy with the potential to provide clinically relevant information while reducing the time, cost, and patient burden associated with clinical trials.
doi_str_mv 10.1016/j.jval.2020.06.006
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2449953686</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1098301520322026</els_id><sourcerecordid>2455932911</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-dcd538e57c9843cbfa0a2ca1e9d32672cf4178863d88dca9d6f4e391f2173753</originalsourceid><addsrcrecordid>eNp9kE1Lw0AURQdRbK3-ARcScOMmcT6TDLgp_VChUNCKy2E6MykJaSfOJIX-eye0unDh6r3FefddDgC3CCYIovSxSqq9rBMMMUxgmkCYnoEhYpjGNCPkPOyQ5zGBiA3AlfcVDATB7BIMCIEEZzkcgumHN5Etojcj6_jTulpHs32pzU6ZqLXRe9c01rXRfDqOxk3jbHjY48udsrXdHKKp6zb-GlwUsvbm5jRHYDWfrSYv8WL5_DoZL2JFOW1jrTQjuWGZ4jklal1IKLGSyHBNcJphVVCU5XlKdJ5rJblOC2oIRwVGGckYGYGHY2zo8dUZ34pt6ZWpa7kztvMCU8o5I2lIGIH7P2hlO7cL5QLFGCeYIxQofKSUs947U4jGlVvpDgJB0SsWlegVi16xgKnoBY7A3Sm6W2-N_j35cRqApyNggop9aZzwquyF6tIZ1Qpty__yvwHX0opk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2455932911</pqid></control><display><type>article</type><title>Use of Real-World Evidence to Support FDA Approval of Oncology Drugs</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Feinberg, Bruce A. ; Gajra, Ajeet ; Zettler, Marjorie E. ; Phillips, Todd D. ; Phillips, Eli G. ; Kish, Jonathan K.</creator><creatorcontrib>Feinberg, Bruce A. ; Gajra, Ajeet ; Zettler, Marjorie E. ; Phillips, Todd D. ; Phillips, Eli G. ; Kish, Jonathan K.</creatorcontrib><description>Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the efficacy of oncology drugs for Food and Drug Administration (FDA) approval has not been described. In this paper, we review 5 recent examples where RWE was submitted in support of the FDA approvals of original or supplementary indications for oncology drugs. To identify cases where RWE was used, we reviewed drug approval packages available at Drugs@FDA for oncology drugs approved between 2017 and 2019. Five cases were selected to present a broad overview of different types of RWE, different circumstances under which RWE has been used for regulatory approvals, and how FDA evaluated the data in each case. The type of RWE submitted, the indication, limitations identified by FDA reviewers, and the outcome of the submission are discussed. RWE, particularly historical controls for rare or orphan indications, has been used to support both original and supplementary oncology drug approvals. Types of RWE included data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies. Small sample sizes, data quality, and methodological issues were among concerns cited by FDA reviewers. By bridging the gap between the constraints of the trial setting and the realities of clinical practice, RWE can add value to a regulatory submission. These early examples provide insight into how regulators evaluated RWE submitted as evidence of efficacy for oncology drugs. •In accordance with the 21st Century Cures Act directive, the Food and Drug Administration (FDA) is evaluating the potential for real-world evidence (RWE) to support the approval of supplementary indications or fulfill post-approval study requirements for drugs.•Our analysis found that significant precedent exists for the FDA’s acceptance of RWE (including data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies) to support oncology drug approvals, especially for rare or orphan indications.•The use of RWE to support drug approval is a viable strategy with the potential to provide clinically relevant information while reducing the time, cost, and patient burden associated with clinical trials.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2020.06.006</identifier><identifier>PMID: 33032780</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antineoplastic Agents - standards ; Antineoplastic Agents - therapeutic use ; Clinical medicine ; Clinical research ; Clinical trials ; Computerized medical records ; Data quality ; Drug Approval - methods ; Drug Approval - organization &amp; administration ; Drug delivery systems ; Efficacy ; Electronic medical records ; Evidence-Based Practice - standards ; FDA approval ; Food and Drug Administration ; Health records ; Healthy food ; Humans ; Marketing ; Methodological problems ; Neoplasms - drug therapy ; Oncology ; oncology drug approval ; Pragmatic Clinical Trials as Topic - methods ; Pragmatic Clinical Trials as Topic - standards ; Prescription drugs ; real-world data ; real-world evidence ; United States ; United States Food and Drug Administration - standards</subject><ispartof>Value in health, 2020-10, Vol.23 (10), p.1358-1365</ispartof><rights>2020 ISPOR–The Professional Society for Health Economics and Outcomes Research</rights><rights>Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Oct 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-dcd538e57c9843cbfa0a2ca1e9d32672cf4178863d88dca9d6f4e391f2173753</citedby><cites>FETCH-LOGICAL-c494t-dcd538e57c9843cbfa0a2ca1e9d32672cf4178863d88dca9d6f4e391f2173753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jval.2020.06.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,30999,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33032780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Feinberg, Bruce A.</creatorcontrib><creatorcontrib>Gajra, Ajeet</creatorcontrib><creatorcontrib>Zettler, Marjorie E.</creatorcontrib><creatorcontrib>Phillips, Todd D.</creatorcontrib><creatorcontrib>Phillips, Eli G.</creatorcontrib><creatorcontrib>Kish, Jonathan K.</creatorcontrib><title>Use of Real-World Evidence to Support FDA Approval of Oncology Drugs</title><title>Value in health</title><addtitle>Value Health</addtitle><description>Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the efficacy of oncology drugs for Food and Drug Administration (FDA) approval has not been described. In this paper, we review 5 recent examples where RWE was submitted in support of the FDA approvals of original or supplementary indications for oncology drugs. To identify cases where RWE was used, we reviewed drug approval packages available at Drugs@FDA for oncology drugs approved between 2017 and 2019. Five cases were selected to present a broad overview of different types of RWE, different circumstances under which RWE has been used for regulatory approvals, and how FDA evaluated the data in each case. The type of RWE submitted, the indication, limitations identified by FDA reviewers, and the outcome of the submission are discussed. RWE, particularly historical controls for rare or orphan indications, has been used to support both original and supplementary oncology drug approvals. Types of RWE included data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies. Small sample sizes, data quality, and methodological issues were among concerns cited by FDA reviewers. By bridging the gap between the constraints of the trial setting and the realities of clinical practice, RWE can add value to a regulatory submission. These early examples provide insight into how regulators evaluated RWE submitted as evidence of efficacy for oncology drugs. •In accordance with the 21st Century Cures Act directive, the Food and Drug Administration (FDA) is evaluating the potential for real-world evidence (RWE) to support the approval of supplementary indications or fulfill post-approval study requirements for drugs.•Our analysis found that significant precedent exists for the FDA’s acceptance of RWE (including data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies) to support oncology drug approvals, especially for rare or orphan indications.•The use of RWE to support drug approval is a viable strategy with the potential to provide clinically relevant information while reducing the time, cost, and patient burden associated with clinical trials.</description><subject>Antineoplastic Agents - standards</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Clinical medicine</subject><subject>Clinical research</subject><subject>Clinical trials</subject><subject>Computerized medical records</subject><subject>Data quality</subject><subject>Drug Approval - methods</subject><subject>Drug Approval - organization &amp; administration</subject><subject>Drug delivery systems</subject><subject>Efficacy</subject><subject>Electronic medical records</subject><subject>Evidence-Based Practice - standards</subject><subject>FDA approval</subject><subject>Food and Drug Administration</subject><subject>Health records</subject><subject>Healthy food</subject><subject>Humans</subject><subject>Marketing</subject><subject>Methodological problems</subject><subject>Neoplasms - drug therapy</subject><subject>Oncology</subject><subject>oncology drug approval</subject><subject>Pragmatic Clinical Trials as Topic - methods</subject><subject>Pragmatic Clinical Trials as Topic - standards</subject><subject>Prescription drugs</subject><subject>real-world data</subject><subject>real-world evidence</subject><subject>United States</subject><subject>United States Food and Drug Administration - standards</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNp9kE1Lw0AURQdRbK3-ARcScOMmcT6TDLgp_VChUNCKy2E6MykJaSfOJIX-eye0unDh6r3FefddDgC3CCYIovSxSqq9rBMMMUxgmkCYnoEhYpjGNCPkPOyQ5zGBiA3AlfcVDATB7BIMCIEEZzkcgumHN5Etojcj6_jTulpHs32pzU6ZqLXRe9c01rXRfDqOxk3jbHjY48udsrXdHKKp6zb-GlwUsvbm5jRHYDWfrSYv8WL5_DoZL2JFOW1jrTQjuWGZ4jklal1IKLGSyHBNcJphVVCU5XlKdJ5rJblOC2oIRwVGGckYGYGHY2zo8dUZ34pt6ZWpa7kztvMCU8o5I2lIGIH7P2hlO7cL5QLFGCeYIxQofKSUs947U4jGlVvpDgJB0SsWlegVi16xgKnoBY7A3Sm6W2-N_j35cRqApyNggop9aZzwquyF6tIZ1Qpty__yvwHX0opk</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Feinberg, Bruce A.</creator><creator>Gajra, Ajeet</creator><creator>Zettler, Marjorie E.</creator><creator>Phillips, Todd D.</creator><creator>Phillips, Eli G.</creator><creator>Kish, Jonathan K.</creator><general>Elsevier Inc</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7X8</scope></search><sort><creationdate>202010</creationdate><title>Use of Real-World Evidence to Support FDA Approval of Oncology Drugs</title><author>Feinberg, Bruce A. ; Gajra, Ajeet ; Zettler, Marjorie E. ; Phillips, Todd D. ; Phillips, Eli G. ; Kish, Jonathan K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-dcd538e57c9843cbfa0a2ca1e9d32672cf4178863d88dca9d6f4e391f2173753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antineoplastic Agents - standards</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Clinical medicine</topic><topic>Clinical research</topic><topic>Clinical trials</topic><topic>Computerized medical records</topic><topic>Data quality</topic><topic>Drug Approval - methods</topic><topic>Drug Approval - organization &amp; administration</topic><topic>Drug delivery systems</topic><topic>Efficacy</topic><topic>Electronic medical records</topic><topic>Evidence-Based Practice - standards</topic><topic>FDA approval</topic><topic>Food and Drug Administration</topic><topic>Health records</topic><topic>Healthy food</topic><topic>Humans</topic><topic>Marketing</topic><topic>Methodological problems</topic><topic>Neoplasms - drug therapy</topic><topic>Oncology</topic><topic>oncology drug approval</topic><topic>Pragmatic Clinical Trials as Topic - methods</topic><topic>Pragmatic Clinical Trials as Topic - standards</topic><topic>Prescription drugs</topic><topic>real-world data</topic><topic>real-world evidence</topic><topic>United States</topic><topic>United States Food and Drug Administration - standards</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feinberg, Bruce A.</creatorcontrib><creatorcontrib>Gajra, Ajeet</creatorcontrib><creatorcontrib>Zettler, Marjorie E.</creatorcontrib><creatorcontrib>Phillips, Todd D.</creatorcontrib><creatorcontrib>Phillips, Eli G.</creatorcontrib><creatorcontrib>Kish, Jonathan K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feinberg, Bruce A.</au><au>Gajra, Ajeet</au><au>Zettler, Marjorie E.</au><au>Phillips, Todd D.</au><au>Phillips, Eli G.</au><au>Kish, Jonathan K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Real-World Evidence to Support FDA Approval of Oncology Drugs</atitle><jtitle>Value in health</jtitle><addtitle>Value Health</addtitle><date>2020-10</date><risdate>2020</risdate><volume>23</volume><issue>10</issue><spage>1358</spage><epage>1365</epage><pages>1358-1365</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the efficacy of oncology drugs for Food and Drug Administration (FDA) approval has not been described. In this paper, we review 5 recent examples where RWE was submitted in support of the FDA approvals of original or supplementary indications for oncology drugs. To identify cases where RWE was used, we reviewed drug approval packages available at Drugs@FDA for oncology drugs approved between 2017 and 2019. Five cases were selected to present a broad overview of different types of RWE, different circumstances under which RWE has been used for regulatory approvals, and how FDA evaluated the data in each case. The type of RWE submitted, the indication, limitations identified by FDA reviewers, and the outcome of the submission are discussed. RWE, particularly historical controls for rare or orphan indications, has been used to support both original and supplementary oncology drug approvals. Types of RWE included data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies. Small sample sizes, data quality, and methodological issues were among concerns cited by FDA reviewers. By bridging the gap between the constraints of the trial setting and the realities of clinical practice, RWE can add value to a regulatory submission. These early examples provide insight into how regulators evaluated RWE submitted as evidence of efficacy for oncology drugs. •In accordance with the 21st Century Cures Act directive, the Food and Drug Administration (FDA) is evaluating the potential for real-world evidence (RWE) to support the approval of supplementary indications or fulfill post-approval study requirements for drugs.•Our analysis found that significant precedent exists for the FDA’s acceptance of RWE (including data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies) to support oncology drug approvals, especially for rare or orphan indications.•The use of RWE to support drug approval is a viable strategy with the potential to provide clinically relevant information while reducing the time, cost, and patient burden associated with clinical trials.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33032780</pmid><doi>10.1016/j.jval.2020.06.006</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2020-10, Vol.23 (10), p.1358-1365
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_miscellaneous_2449953686
source MEDLINE; Elsevier ScienceDirect Journals Complete; Applied Social Sciences Index & Abstracts (ASSIA); EZB-FREE-00999 freely available EZB journals
subjects Antineoplastic Agents - standards
Antineoplastic Agents - therapeutic use
Clinical medicine
Clinical research
Clinical trials
Computerized medical records
Data quality
Drug Approval - methods
Drug Approval - organization & administration
Drug delivery systems
Efficacy
Electronic medical records
Evidence-Based Practice - standards
FDA approval
Food and Drug Administration
Health records
Healthy food
Humans
Marketing
Methodological problems
Neoplasms - drug therapy
Oncology
oncology drug approval
Pragmatic Clinical Trials as Topic - methods
Pragmatic Clinical Trials as Topic - standards
Prescription drugs
real-world data
real-world evidence
United States
United States Food and Drug Administration - standards
title Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T12%3A51%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Real-World%20Evidence%20to%20Support%20FDA%20Approval%20of%20Oncology%20Drugs&rft.jtitle=Value%20in%20health&rft.au=Feinberg,%20Bruce%20A.&rft.date=2020-10&rft.volume=23&rft.issue=10&rft.spage=1358&rft.epage=1365&rft.pages=1358-1365&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2020.06.006&rft_dat=%3Cproquest_cross%3E2455932911%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2455932911&rft_id=info:pmid/33032780&rft_els_id=S1098301520322026&rfr_iscdi=true